Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer

• Главные авторы: Gabrielle P. Dailey (Автор), Christopher A. Rabiola (Автор), Gangjun Lei (Автор), Junping Wei (Автор), Xiao-Yi Yang (Автор), Tao Wang (Автор), Cong-Xiao Liu (Автор), Melissa Gajda (Автор), Amy C. Hobeika (Автор), Amanda Summers (Автор), Robert D. Marek (Автор), Michael A. Morse (Автор), Herbert K. Lyerly (Автор), Erika J. Crosby (Автор), Zachary C. Hartman (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

ABSTRACTER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (ESR1), which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment inevitably results in therapeutic resistance, whic...